Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06731803 |
Title | Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (NeoART) |
Acronym | NeoART |
Recruitment | Not yet recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | DEU |